LIMK2 and osteosarcoma: Ultimately, these findings, obtained through genetic enhancement of autophagy combined with treatment with a cytoskeleton signaling pathway inhibitor, indicated that anlotinib-induced autophagy promoted the metastasis of human osteosarcoma cells via RhoA-ROCK-LIMK2 signaling and EMT.